• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.

作者信息

Benotmane Ilies, Jungbauer-Groznica Martin, Staropoli Isabelle, Planas Delphine, Dehan Océane, Brisebarre Angela, Simon-Loriere Etienne, Fafi-Kremer Samira, Schwartz Olivier, Bruel Timothée, Caillard Sophie

机构信息

Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France.

Institut national de la santé et de la recherche médicale (Inserm) UMR S1109, LabEx Transplantex, Fédération de médecine translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

出版信息

Transpl Int. 2024 Jul 16;37:13272. doi: 10.3389/ti.2024.13272. eCollection 2024.

DOI:10.3389/ti.2024.13272
PMID:39081903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11286486/
Abstract
摘要

相似文献

1
and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.肾移植受者中抗SARS-CoV-2变体单克隆抗体的中和效力
Transpl Int. 2024 Jul 16;37:13272. doi: 10.3389/ti.2024.13272. eCollection 2024.
2
CoronaVac-vaccinated kidney transplant recipients with hybrid immunity have strong neutralizing responses against Omicron and Mu variants of SARS-CoV-2.具有混合免疫的科兴疫苗接种肾移植受者对新冠病毒奥密克戎和缪毒株具有强烈的中和反应。
Braz J Microbiol. 2024 Dec;55(4):3303-3308. doi: 10.1007/s42770-024-01507-7. Epub 2024 Sep 10.
3
Enhanced SARS-CoV-2 BA.2.86 Neutralization After BA.5 Infection in Vaccinated Kidney Transplant Recipients.接种疫苗的肾移植受者感染BA.5后对SARS-CoV-2 BA.2.86的中和作用增强。
Transplant Proc. 2025 Jul-Aug;57(6):1013-1017. doi: 10.1016/j.transproceed.2025.05.021. Epub 2025 Jun 28.
4
Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.新冠病毒感染后6个月内肾移植受者体内抗新冠病毒抗体的下降与丧失
Kidney Int. 2021 Feb;99(2):486-488. doi: 10.1016/j.kint.2020.12.001.
5
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.mRNA 疫苗接种后肾移植受者对 SARS-CoV-2 奥密克戎亚变种的中和抗体反应和细胞反应。
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
6
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.肾移植受者接种第三剂新冠病毒疫苗可诱导对疫苗和奥密克戎变异株的抗体反应，但免疫球蛋白亚类转换有限。
Microbiol Spectr. 2025 Mar 4;13(3):e0219024. doi: 10.1128/spectrum.02190-24. Epub 2025 Jan 31.
7
Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients.肾移植受者感染奥密克戎或接种奥密克戎BA.4/5疫苗后对SARS-CoV-2刺突蛋白免疫反应的比较。
Front Immunol. 2025 Jan 14;15:1476294. doi: 10.3389/fimmu.2024.1476294. eCollection 2024.
8
Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.免疫抑制个体和健康个体接种单价奥密克戎JN.1适应性mRNA新冠疫苗后的中和抗体及T细胞针对刺突蛋白的反应
J Med Virol. 2025 Jun;97(6):e70463. doi: 10.1002/jmv.70463.
9
Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.肾移植受者和透析患者对 SARS-CoV-2 的体液免疫：SARS-CoV-2 感染和接种疫苗后解析的 IgA 和 IgG 模式。
Virol J. 2024 Jun 13;21(1):138. doi: 10.1186/s12985-024-02410-1.
10
Attenuated neutralization, maintained specificity: Humoral response to SARS-CoV-2 booster in kidney allograft recipients.中和作用减弱，特异性保持：肾移植受者对 SARS-CoV-2 加强针的体液反应。
Diagn Microbiol Infect Dis. 2025 Jan;111(1):116550. doi: 10.1016/j.diagmicrobio.2024.116550. Epub 2024 Oct 16.

本文引用的文献

1
SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.SARS-CoV-2 BA.1 和 BA.2 突破感染可增强对早期奥密克戎亚变种的抗体反应，但对 BQ.1.1 或 XBB.1.5 无效。
Cell Rep Med. 2024 Mar 19;5(3):101474. doi: 10.1016/j.xcrm.2024.101474.
2
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.索托维单抗疗法在免疫功能低下患者的血清中引发针对奥密克戎BQ.1.1和XBB.1.5的抗病毒活性。
Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007.
3
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
严重急性呼吸综合征冠状病毒2型BA.2.86变体的传播性、传染性和免疫逃逸
Lancet Infect Dis. 2023 Nov;23(11):e460-e461. doi: 10.1016/S1473-3099(23)00575-3. Epub 2023 Sep 18.
4
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.高剂量静脉注射索托维单抗治疗轻至中度COVID-19的安全性、病毒学、药代动力学及临床经验：一项开放标签临床试验
Open Forum Infect Dis. 2023 Jul 10;10(7):ofad344. doi: 10.1093/ofid/ofad344. eCollection 2023 Jul.
5
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.检测接种疫苗或单克隆抗体治疗后，针对 SARS-CoV-2 的中和抗体的保护作用。
Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w.
6
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.抗体介导的对有症状 COVID-19 的保护作用可以在低血清中和滴度下实现。
Sci Transl Med. 2023 Mar 22;15(688):eadg2783. doi: 10.1126/scitranslmed.adg2783.
7
Kidney Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to COVID-19.肾移植和透析患者因 COVID-19 而死亡的风险仍然较高。
Transplantation. 2023 May 1;107(5):1136-1138. doi: 10.1097/TP.0000000000004462. Epub 2023 Apr 22.
8
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
9
Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.COVID-19 治疗药物在实体器官移植受者中的应用进展，包括奥密克戎变异株。
Transplantation. 2022 Aug 1;106(8):1528-1537. doi: 10.1097/TP.0000000000004200. Epub 2022 Jul 22.
10
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.在肾移植受者中，感染或第三次接种 mRNA 疫苗会引发针对 SARS-CoV-2 的中和抗体反应。
Sci Transl Med. 2022 Mar 16;14(636):eabl6141. doi: 10.1126/scitranslmed.abl6141.